Type1 Diabetes Mellitus Clinical Trial
Official title:
Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus
Approximately 80 patients will be enrolled in the study from China and randomized in a 1:1 ratio to one of the 2 treatment arms:diabetes diet+highland barley diet; or diabetes diet. Study treatment will continue for 12 weeks. The primary efficacy measure is the change in MAGE from continuous glucose monitoring system at 12 weeks. The study consists of 3 periods: a 1-week screening (period A), a 8-day run-in period (period B) and a 12-week treatment period (period C). Continuous glucose monitoring system will be used in baseline and endpoint.
This is a prospective, randomized, open-label comparison of the effects and safety of barley meal plus diabetes diet on blood glucose fluctuations in patients with type 1 diabetes (T1DM) using multiple daily insulin injections (MDI). , parallel test. About 80 patients with T1DM were enrolled in the preliminary trial. During the lead-in period, no interventions were given to the patient's diet from day 1 to day 4, and diabetes diet education and guidance were given from day 5 to day 8, depending on the patient's blood glucose and diet. Personalization of habits, weights, and activities, etc., establish a diabetes diet. At the end of the lead-in period, patients were randomly divided into two treatment groups according to the ratio of 1:1: Observation group: Diabetes diet + barley diet. (The barley meal group diet was formulated according to the diabetes diet, but each meal was replaced with 20g barley nutrition powder and other calories instead of part of the diet. In the control group: Diabetes diet; dietary treatment after randomization will continue for 12 weeks. From the induction period to the treatment period 6 days, treatment period 10-12 weeks ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Withdrawn |
NCT03396484 -
Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT03117998 -
Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
|
Phase 2 | |
Recruiting |
NCT03369821 -
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
|
||
Completed |
NCT03202732 -
DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes
|
N/A | |
Completed |
NCT03704818 -
Dapagliflozin Effects on Hypoglycemia
|
Phase 1 | |
Recruiting |
NCT03864991 -
Lifestyle Changes and Glycemic Control in T1D
|
N/A | |
Completed |
NCT03725657 -
Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
|
||
Completed |
NCT02985866 -
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
|
N/A | |
Completed |
NCT03003806 -
Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study
|
N/A | |
Withdrawn |
NCT04147637 -
FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia
|
N/A | |
Completed |
NCT03970889 -
Real-time Reminders To Decrease Late or Missed Meal Boluses
|
N/A | |
Recruiting |
NCT04589325 -
Ixekizumab Diabetes Intervention Trial (I-DIT)
|
Phase 2 | |
Completed |
NCT03367390 -
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
|
Phase 1 | |
Completed |
NCT03738852 -
Mechanisms for Restoration of Hypoglycemia Awareness
|
Early Phase 1 | |
Completed |
NCT03406585 -
Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03859856 -
Ovarian Reserve in Diabetes Mellitus
|
||
Withdrawn |
NCT04102202 -
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
|
Phase 1/Phase 2 | |
Terminated |
NCT03353792 -
Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients
|
N/A | |
Recruiting |
NCT03811470 -
China Diabetes Registry by Metabolic Management Center
|